Discharge medical treatment implementation in patients admitted for AHF: preliminary data from the BRING–UP3 HF study
Abstract
Recent ESC guidelines introduced a new treatment paradigm for HFrEF, with a novel four pillar therapeutic approach comprising ACE–I/ARBs/ARNIs, Beta–blockers, MRAs, and SGLT2i. Furthermore, these guidelines for the first time give a Class IA recommendation for Empagliflozin and Dapagliflozin in HFmrEF and HFpEF. Evaluation of transferability of RCTs derived evidence to clinical practice and guideline recommendation implementation are two major issues. Hospital admission is considered an important chance for treatment optimization.
To describe discharge treatments of acute heart failure (AHF) patients enrolled by Italian cardiology sites participating to the nationwide BRING–UP3 HF study.
BRING–UP–3 HF study is an observational prospective, nationwide investigation involving 179 sites and enrolling ambulatory or hospitalized HF patients in two three–month periods, followed by a six–month follow–up with end–point evaluation. For HF with reduced ejection fraction (HFrEF), the objective is to describe the prescription rate of the four pillars. Baseline enrollment data for the hospitalized cohort (Phase I) are here presented. Overall, 1373 patients were included. Mean age was 71±12 years (40.6% 75+ years) and 29.8% were females. A high percentage of patients (42.7%) had de novo HF. Patients with HFrEF were prevalent (70%), followed by HFpEF (16%) and HFmrEF (14%). History of hypertension, atrial fibrillation, diabetes mellitus, and chronic kidney disease was reported in 74.7%,…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 1,373 participants or records.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.